advertisement

Accelerate your drug discovery pipeline with AI-powered molecular modelling

BioSim Pro · Trusted by 400+ research institutions globally · 30-day free trial

Learn More
Monday, 23 March 2026

BIOMED

TODAY

Biomedical Science · Made Accessible

Subscribe
Breaking
CRISPR base editing corrects sickle cell mutation in 97% of patient cells · Phase III mRNA cancer vaccine shows 44% reduction in recurrence · Gut microbiome linked to treatment-resistant depression — Nature study · Novo Nordisk acquires rare disease biotech for $3.2B · FDA grants breakthrough designation to novel Alzheimer's antibody ·
CRISPR base editing corrects sickle cell mutation in 97% of patient cells · Phase III mRNA cancer vaccine shows 44% reduction in recurrence · Gut microbiome linked to treatment-resistant depression — Nature study · Novo Nordisk acquires rare disease biotech for $3.2B · FDA grants breakthrough designation to novel Alzheimer's antibody ·
  • Legal & Privacy

Legal & Privacy Centre · Updated April 2026

Transparency & Your Rights

Biomed Today is committed to being clear, honest and fair about how we operate. This page covers our Privacy Policy, Terms of Use, Accessibility Statement, and Cookie Settings — everything you need to understand your rights and how we handle your information.

Accessibility Statement

Effective: April 2026 · Last reviewed: April 2026

Our goal: Biomed Today aims to meet WCAG 2.1 Level AA accessibility standards. If you experience any difficulty using our site, please contact us at biomedtodaynews@gmail.com and we will assist you.

Our Commitment

Biomed Today is committed to making biomedical science accessible to everyone. We believe researchers, clinicians, students, and science professionals of all abilities should be able to access, read, and benefit from our content without barriers. We aim to meet the Web Content Accessibility Guidelines (WCAG) 2.1 at Level AA across our website and recognise this is an ongoing commitment.

What We Do

  • We use semantic, well-structured HTML to support screen readers and other assistive technologies
  • We maintain sufficient colour contrast between text and backgrounds across all sections
  • Navigation, search bars, form fields, and buttons are operable by keyboard without requiring a mouse
  • Our website is responsive and readable across a range of devices including mobile phones and tablets
  • We provide descriptive text for images where meaningful to the content
  • Interactive elements have clear visible focus indicators for keyboard navigation

Known Limitations

Some third-party content — including graphical abstracts, research images, and scientific figures submitted by external organisations — may not always include complete accessibility attributes such as alternative text. We are working to address this progressively. Some embedded content and external links may not meet WCAG 2.1 AA standards as those resources are outside our direct control.

Feedback and Contact

We welcome feedback on the accessibility of our website. If you encounter a barrier or experience difficulty accessing any content on Biomed Today, please contact us at biomedtodaynews@gmail.com. Please describe the difficulty you experienced and which page it relates to. We will respond within five working days and provide content in an alternative format where possible.

Technical Information

This statement was prepared in April 2026. It was prepared based on our own assessment of the Biomed Today website. We are not subject to the Public Sector Bodies Accessibility Regulations 2018 as we are not a public sector body, however we voluntarily commit to meeting these standards as best practice for a professional science publication serving a global research community.

Legal Pages

Data & Privacy Enquiries

For any question about your data, your rights, or this policy, contact us directly. We respond within 30 working days.

  • biomedtodaynews@gmail.com

Policy Dates

  • Privacy Policy                              Apr 2026
  • Terms of Use                                Apr 2026
  • Accessibility                                 Apr 2026
  • Cookie Policy                              Apr 2026